Home › Companies › ELVN

Pipeline (1 active programs)

Discontinued (1)

• ELVN-002 — undisclosed · strategic deprioritization (exploring strategic alternatives; no longer pursuing development)

Capital (as filed)

Cash

$152M cash and cash equivalents · Sep 30, 2026 (10-Q)

Short-term investments

$733M Sep 30, 2026

Operating cash flow

−$12.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$895M cash, runway into 2030 per the deep dive of Oct 23, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

• 2026-10-26 Enliven Therapeutics (ELVN) - Scientific Deep Dive for Relcobatinib (ELVN-001) and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Enliven Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-10-26 Watch Enliven Therapeutics (ELVN) - Scientific Deep Dive for Relcobatinib (ELVN-001) and Pipeline Products Relcobatinib has a winnable Phase 3 but ENABLE-2 is designed to beat generic 2G TKIs rather than asciminib or MK-4208, and at $41.93 the stock already prices a successful 2L+ franchise plus much of a first-line future that has no trial yet.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (19)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 5, 2026ReleaseEnliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdateSummary on the 8-K
• Nov 5, 20268-KCurrent report: results of operations · EX-99.1Enliven has locked in FDA alignment on the final ENABLE-2 Phase 3 design and is on track to dose the first patient before year-end — clearing the last major setup hurdle the thesis was waiting on, while Q3 spend signals the burn rate is accelerating materially as pivotal infrastructure spins up.
• Nov 5, 202610-QQuarterly reportSummary on the 8-K
• Oct 14, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
• Aug 5, 20268-KCurrent report: results of operations · EX-99.1
• Aug 5, 202610-QQuarterly report
• Jun 24, 2026SCHEDULE 13D/A13D amendment
• Jun 17, 2026SCHEDULE 13D/A13D amendment
• Jun 12, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1
• Jun 12, 2026424B5Prospectus supplement (offering)
• Jun 11, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
• Jun 11, 2026424B5Prospectus supplement (offering)
• Jun 10, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
• May 7, 20268-KCurrent report: results of operations · EX-99.1
• May 7, 202610-QQuarterly report
• Apr 27, 2026DEFA14AProxy soliciting material
• Apr 27, 2026DEF 14AProxy statement
• Mar 3, 20268-KCurrent report: results of operations · EX-99.1
• Mar 3, 202610-KAnnual report